Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical ruxolitinib evaluation in Prurigo Nodularis (TRuE-PN2)
2022-502461-23-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Ruxolitinib cream with Vehicle cream (2 arms). Primary endpoint: WI-NRS4 response at Week 12. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2022-502461-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502461-23-00.